Chinese Journal of Cancer Research最新文献

{"title":"Health economic evaluation on population-based <i>Helicobacter pylori</i> eradication and endoscopic screening for gastric cancer prevention.","authors":"Zhiqiang Hu, Zongchao Liu, Wenqing Li, Weicheng You, Kaifeng Pan","doi":"10.21147/j.issn.1000-9604.2023.06.04","DOIUrl":"10.21147/j.issn.1000-9604.2023.06.04","url":null,"abstract":"<p><p>Gastric cancer is a global public health burden, nearly one million new cases are diagnosed per year worldwide, of which 44% of cases occur in China. The prognosis of gastric cancer varies remarkably by the stage of cancer, and most of the patients in China are diagnosed at advanced stages, resulting in poor prognoses. Effective strategies to reduce the burden of gastric cancer include primary prevention through testing and treatment of <i>Helicobacter pylori</i> (<i>H. pylori</i>) and secondary prevention by screening and early detection. Although many countries have issued management guidelines and consensus reports concerning these strategies, the limited availability of healthcare resources often precludes their widespread implementation. Therefore, assessing the costs, benefits, and harms of population-based intervention measures through health economic evaluation is necessary for informed health policy decisions. Accordingly, we synthesize management approaches from different countries on <i>H. pylori</i> eradication and endoscopic screening, and also summarize recent advancements in health economic evaluations on population-based preventive strategies. The goal of the review is to provide empirical evidence supporting optimal resource allocation, maximizing benefits for the population, and ultimately reducing the burden of gastric cancer.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 6","pages":"595-605"},"PeriodicalIF":0.0,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139418741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benchmark for establishment of organoids from gastrointestinal epithelium and cancer based on available consumables and reagents.","authors":"Ruixin Yang, Zhen Xiang, Ranlin Yan, Wingyan Kwan, Lu Zang, Zhenggang Zhu, Yao Qi, Yanping Xu, Xiaoyan Zhang, Hengjun Gao, Yingyan Yu","doi":"10.21147/j.issn.1000-9604.2023.06.08","DOIUrl":"10.21147/j.issn.1000-9604.2023.06.08","url":null,"abstract":"<p><p>Gastrointestinal cancers are a public health problem that threatens the lives of human being. A good experimental model is a powerful tool to promote the uncovering pathogenesis and establish novel treatment methods. High-quality biomedical research requires experimental models to recapitulate the physiological and pathological states of their parental tissues as much as possible. Organoids are such experimental models. Organoids refer to small organ-like cellular clusters formed by the expansion and passaging of living tissues in 3D culture medium <i>in vitro</i>. Organoids are highly similar to the original tissues in terms of cellular composition, cell functions, and genomic profiling. Organoids have many advantages, such as short preparation cycles, long-term storage based on cryopreservation, and reusability. In recent years, researchers carried out the establishment of organoids from gastrointestinal mucosa and cancer tissues, and accumulated valuable experiences. In order to promote effective usage and further development of organoid-related technologies in the research of gastrointestinal diseases, this study proposes a benchmark based on utilization of available experimental consumables and reagents, which are involved in the key steps such as collection and pretreatment of biospecimen, organoid construction, organoid cryopreservation and recovery, growth status evaluation, and organoid quality control. We believe that the standard for the construction and preservation of organoids derived from human gastrointestinal epithelium and cancer tissues can provide an important reference for the majority of scientific researchers.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 6","pages":"636-644"},"PeriodicalIF":0.0,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139418735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring ideal operative time for best outcomes in gastric cancer surgery: A multi-institutional study based on KLASS-07 database.","authors":"Shin-Hoo Park, Ye-Rim Shin, Hoon Hur, Chang Min Lee, Jae Seok Min, Seung Wan Ryu, Hyun Dong Chae, Oh Jeong, Chang-In Choi, Kyo-Young Song, Ho Goon Kim, Ye Seob Jee, Kwang Hee Kim, Jeong Goo Kim, Kyung Sook Yang, Hua Huang, Sungsoo Park","doi":"10.21147/j.issn.1000-9604.2023.06.10","DOIUrl":"10.21147/j.issn.1000-9604.2023.06.10","url":null,"abstract":"<p><strong>Objective: </strong>While a rushed operation can omit essential procedures, prolonged operative time results in higher morbidity. Nevertheless, the optimal operative time range remains uncertain. This study aimed to estimate the ideal operative time range and evaluate its applicability in laparoscopic cancer surgery.</p><p><strong>Methods: </strong>A prospectively collected multicenter database of 397 patients who underwent laparoscopic distal gastrectomy were retrospectively reviewed. The ideal operative time range was statistically calculated by separately analyzing the operative time of uneventful surgeries. Finally, intraoperative and postoperative outcomes were compared among the shorter, ideal, and longer operative time groups.</p><p><strong>Results: </strong>The statistically calculated ideal operative time was 135.4-165.4 min. The longer operative time (LOT) group had a lower rate of uneventful, perfect surgery than the ideal or shorter operative time (IOT/SOT) group (2.8% <i>vs.</i> 8.8% and 2.2% <i>vs.</i> 13.4%, all P<0.05). Longer operative time increased bleeding, postoperative morbidities, and delayed diet and discharge (all P<0.05). Particularly, an uneventful, perfect surgery could not be achieved when the operative time exceeded 240 min. Regardless of ideal time range, SOT group achieved the highest percentage of uneventful surgery (13.4%), which was possible by surgeon's ability to retrieve a higher number of lymph nodes and perform ≥150 gastrectomies annually.</p><p><strong>Conclusions: </strong>Operative time longer than the ideal time range (especially ≥240 min) should be avoided. If the essential operative procedure were faithfully conducted without compromising oncological safety, an operative time shorter than the ideal range leaded to a better prognosis. Efforts to minimize operative time should be attempted with sufficient surgical experience.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 6","pages":"660-674"},"PeriodicalIF":0.0,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139418740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on <i>National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)</i>.","authors":"Yong Yang, Zhaoya Gao, Jin Gu","doi":"10.21147/j.issn.1000-9604.2023.05.01","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.05.01","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 5","pages":"431-432"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRD-directed and risk-adapted individualized stratified treatment of AML.","authors":"Yijing Zhao, Hanfei Guo, Yingjun Chang","doi":"10.21147/j.issn.1000-9604.2023.05.04","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.05.04","url":null,"abstract":"<p><p>Measurable residual disease (MRD) has been widely recognized as a biomarker for deeply evaluating complete remission (CR), predicting relapse, guiding pre-emptive interventions, and serving as an endpoint surrogate for drug testing. However, despite the emergence of new technologies, there remains a lack of comprehensive understanding regarding the proper techniques, sample materials, and optimal time points for MRD assessment. In this review, we summarized the MRD methods, sample sources, and evaluation frequency according to the risk category of the European Leukemia Net (ELN) 2022. Additionally, we emphasize the importance of properly utilizing and combining these technologies. We have also refined the flowchart outlining each time point for pre-emptive interventions and intervention paths. The evaluation of MRD in acute myeloid leukemia (AML) is sophisticated, clinically applicable, and technology-dependent, and necessitates standardized approaches and further research.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 5","pages":"451-469"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.","authors":"Jianwei Zhang, Haibin Zhu, Lin Shen, Jie Li, Xiaoyan Zhang, Chunmei Bai, Zhiwei Zhou, Xianrui Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Wenhui Lou, Yihebali Chi, Nong Xu, Yongmei Yin, Yuxian Bai, Tao Zhang, Dianrong Xiu, Jia Chen, Shukui Qin, Xiuwen Wang, Yujie Yang, Haoyun Shi, Xian Luo, Songhua Fan, Weiguo Su, Ming Lu, Jianming Xu","doi":"10.21147/j.issn.1000-9604.2023.05.09","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.05.09","url":null,"abstract":"<p><strong>Objective: </strong>Currently, pre-treatment prediction of patients with pancreatic neuroendocrine tumors with liver metastases (PNELM) receiving surufatinib treatment was unsatisfying. Our objective was to examine the association between radiological characteristics and efficacy/prognosis.</p><p><strong>Methods: </strong>We enrolled patients with liver metastases in the phase III, SANET-p trial (NCT02589821) and obtained contrast-enhanced computed tomography (CECT) images. Qualitative and quantitative parameters including hepatic tumor margins, lesion volumes, enhancement pattern, localization types, and enhancement ratios were evaluated. The progression-free survival (PFS) and hazard ratio (HR) were calculated using Cox's proportional hazard model. Efficacy was analyzed by logistic-regression models.</p><p><strong>Results: </strong>Among 152 patients who had baseline CECT assessments and were included in this analysis, the surufatinib group showed statistically superior efficacy in terms of median PFS compared to placebo across various qualitative and quantitative parameters. In the multivariable analysis of patients receiving surufatinib (N=100), those with higher arterial phase standardized enhancement ratio-peri-lesion (ASER-peri) exhibited longer PFS [HR=0.039; 95% confidence interval (95% CI): 0.003-0.483; P=0.012]. Furthermore, patients with a high enhancement pattern experienced an improvement in the objective response ratio [31.3% <i>vs</i>. 14.7%, odds ratio (OR)=3.488; 95% CI: 1.024-11.875; P=0.046], and well-defined tumor margins were associated with a higher disease control rate (DCR) (89.3% <i>vs</i>. 68.2%, OR=4.535; 95% CI: 1.285-16.011; P=0.019) compared to poorly-defined margins.</p><p><strong>Conclusions: </strong>These pre-treatment radiological features, namely high ASER-peri, high enhancement pattern, and well-defined tumor margins, have the potential to serve as predictive markers of efficacy in patients with PNELM receiving surufatinib.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 5","pages":"526-535"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine.","authors":"Yang Liu, Ya-Nan Ren, Yan Cui, Song Liu, Zhi Yang, Hua Zhu, Nan Li","doi":"10.21147/j.issn.1000-9604.2023.05.05","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.05.05","url":null,"abstract":"<p><p>Nuclear medicine plays an irreplaceable role in the diagnosis and treatment of tumors. Radiopharmaceuticals are important components of nuclear medicine. Among the radiopharmaceuticals approved by the Food and Drug Administration (FDA), radio-tracers targeting prostate-specific membrane antigen (PSMA) and somatostatin receptor (SSTR) have held essential positions in the diagnosis and treatment of prostate cancers and neuroendocrine neoplasms, respectively. In recent years, FDA-approved serials of immune-therapy and targeted therapy drugs targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), and nectin cell adhesion molecule 4 (Nectin 4). How to screen patients suitable for these treatments and monitor the therapy? Nuclear medicine with specific radiopharmaceuticals can visualize the expression level of those targets in systemic lesions and evaluate the efficacy of treatment. In addition to radiopharmaceuticals, imaging equipment is also a key step for nuclear medicine. Advanced equipment including total-body positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI) has been developed, which contribute to the diagnosis and treatment of tumors, as well as the development of new radiopharmaceuticals. Here, we conclude most recently advances of radiopharmaceuticals in nuclear medicine, and they substantially increase the \"arsenal\" of clinicians for tumor therapy.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 5","pages":"470-482"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update of latest data for combined therapy for esophageal cancer using radiotherapy and immunotherapy: A focus on efficacy, safety, and biomarkers.","authors":"Shuping Cheng, Butuo Li, Jinming Yu, Linlin Wang","doi":"10.21147/j.issn.1000-9604.2023.05.06","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.05.06","url":null,"abstract":"<p><p>Esophageal cancer usually has a poor prognosis. Given the significant breakthrough with tumor immunotherapy, an increasing number of clinical studies have demonstrated that the combination of radiotherapy and immune checkpoint inhibitors (ICIs) may have a synergistic effect and good outcome in esophageal cancer. Clinical studies of immunoradiotherapy (iRT) for esophageal cancer have proliferated enormously from 2021 to the present. However, a summary of the efficacy and toxicity of combined therapy to guide esophageal cancer treatment in clinical practice is lacking. For this review, we integrate the latest data to analyze and assess the efficacy and safety of iRT for esophageal cancer. In addition, we discuss better predictive biomarkers, therapeutic options for specific populations, and other challenges to identify directions for future research design.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 5","pages":"483-500"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel multimodal prediction model based on DNA methylation biomarkers and low-dose computed tomography images for identifying early-stage lung cancer.","authors":"Jing Zhang, Haohua Yao, Chunliu Lai, Xue Sun, Xiujuan Yang, Shurong Li, Yubiao Guo, Junhang Luo, Zhihua Wen, Kejing Tang","doi":"10.21147/j.issn.1000-9604.2023.05.08","DOIUrl":"10.21147/j.issn.1000-9604.2023.05.08","url":null,"abstract":"<p><strong>Objective: </strong>DNA methylation alterations are early events in carcinogenesis and immune signalling in lung cancer. This study aimed to develop a model based on short stature homeobox 2 gene (<i>SHOX2</i>)/prostaglandin E receptor 4 gene (<i>PTGER4</i>) DNA methylation in plasma, appearance subtype of pulmonary nodules (PNs) and low-dose computed tomography (LDCT) images to distinguish early-stage lung cancers.</p><p><strong>Methods: </strong>We developed a multimodal prediction model with a training set of 257 individuals. The performance of the multimodal prediction model was further validated in an independent validation set of 42 subjects. In addition, we explored the association between <i>SHOX2</i>/<i>PTGER4</i> DNA methylation and driver gene mutations in lung cancer based on data from The Cancer Genome Atlas (TCGA) portal.</p><p><strong>Results: </strong>There were significant differences between the early-stage lung cancers and benign groups in the methylation levels. The area under a receiver operator characteristic curve (AUC) of <i>SHOX2</i> in patients with solid nodules, mixed ground-glass opacity nodules and pure ground-glass opacity nodules were 0.693, 0.497 and 0.864, respectively, while the AUCs of <i>PTGER4</i> were 0.559, 0.739 and 0.619, respectively. With the highest AUC of 0.894, the novel multimodal prediction model outperformed the Mayo Clinic model (0.519) and LDCT-based deep learning model (0.842) in the independent validation set. Database analysis demonstrated that patients with <i>SHOX2</i>/<i>PTGER4</i> DNA hypermethylation were enriched in <i>TP53</i> mutations.</p><p><strong>Conclusions: </strong>The present multimodal prediction model could more efficiently distinguish early-stage lung cancer from benign PNs. A prognostic index based on DNA methylation and lung cancer driver gene alterations may separate the patients into groups with good or poor prognosis.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 5","pages":"511-525"},"PeriodicalIF":5.1,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic abnormalities assist in pathological diagnosis and EBV-positive cell density impact survival in Chinese angioimmunoblastic T-cell lymphoma patients.","authors":"Yunfei Shi, Haojie Wang, Yanfei Liu, Mengping Long, Ning Ding, Lan Mi, Yumei Lai, Lixin Zhou, Xinting Diao, Xianghong Li, Weiping Liu, Jun Zhu","doi":"10.21147/j.issn.1000-9604.2023.05.10","DOIUrl":"10.21147/j.issn.1000-9604.2023.05.10","url":null,"abstract":"<p><strong>Objective: </strong>To explore the application of genetic abnormalities in the diagnosis of angioimmunoblastic T-cell lymphoma (AITL) and the reliable pathological prognostic factors.</p><p><strong>Methods: </strong>This study included 53 AITL cases, which were reviewed for morphological patterns, immunophenotypes, presence of Hodgkin and Reed-Sternberg (HRS)-like cells, and co-occurrence of B cell proliferation. The Epstein-Barr virus (EBV)-positive cells in tissues were counted, and cases were classified into \"EBV encoded RNA (EBER) high-density\" group if >50/HPF. Targeted exome sequencing was performed.</p><p><strong>Results: </strong>Mutation data can assist AITL diagnosis: 1) with considerable HRS-like cells (20 cases): <i>RHOA</i> mutated in 14 cases (<i>IDH2</i> co-mutated in 3 cases, 4 cases with rare <i>RHOA</i> mutation), <i>TET2</i> was mutated in 5 cases (1 case co-mutated with <i>DNMT3A</i>), and <i>DNMT3A</i> mutated in 1 case; 2) accompanied with B cell lymphoma (7 cases): <i>RHOA</i> mutated in 4 cases (1 case had <i>IDH2</i> mutation), <i>TET2</i> mutated in 2 cases and <i>DNMT3A</i> mutated in 1 case; 3) mimic peripheral T cell lymphoma, not otherwise specified (5 cases): <i>RHOA</i> mutated in 2 cases (<i>IDH2</i> co-mutated in 1 case), <i>TET2</i> mutated in 3 cases, and <i>DNMT3A</i> mutated in 1 case; 4) pattern 1 (1 case), <i>RHOA</i> and <i>TET2</i> co-mutated. Besides <i>RHOA</i>^G17V (30/35), rare variant included <i>RHOA</i>^K18N, <i>RHOA</i>^R68H, <i>RHOA</i>^C83Y, <i>RHOA</i>^D120G and <i>RHOA</i>^G17del, <i>IDH2</i>^R172 co-mutated with <i>IDH2</i>^M397V in one case. There were recurrent mutations of <i>FAT3</i>, <i>PCLO</i> and <i>PIEZO1</i> and genes of epigenetic remodeling, T-cell activation, APC and PI3K/AKT pathway. EBER high-density independently indicated adverse overall survival and progression-free survival (P=0.046 and P=0.008, Kaplan-Meier/log-rank).</p><p><strong>Conclusions: </strong>Over half AITL cases might be confused in diagnosis for certain conditions without mutation data. Targeted exome sequencing with a comprehensive panel is crucial to detect both hot-spot and rare mutation variants for <i>RHOA</i> and <i>IDH2</i> and other recurrent mutated genes in addition to <i>TET2</i> and <i>DNMT3A</i>. EBER high-density independently indicated adverse survival.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 5","pages":"536-549"},"PeriodicalIF":5.1,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}